Segment Performance

Kewaunee Scientific (KEQU) reported strong Q1 fiscal year 2026 results. Sales increased 46.9% to $71.104 million, with pre-tax earnings up 61.3% to $3.920 million. Diluted EPS reached $1.04. The domestic segment saw a 53% sales increase, boosted by the Nu Aire acquisition. International sales rose 30.2%, reflecting improved project delivery. The company is investing in corporate infrastructure to support future growth, anticipating uneven performance for the rest of the year but expects better unadjusted EBITDA than fiscal year 2025. Backlog stood at $205 million.